[ad_1]
Pharming’s Ruconest is encouraging when wearing crown patients
Tuesday April 21, 2020 7:30 a.m.
(ABM FN-Dow Jones) Pharming Group has reported encouraging results with Ruconest treatment of five patients with confirmed Covid-19. The biotech company announced this in advance on Tuesday.
Four men and a woman between 53 and 85 years of age with Covid-19 and related severe pneumonia received Ruconest. The treatment was performed at the University Hospital of Basel in Switzerland.
After treatment with Ruconest, according to the biotechnology company, the fever in four out of five patients disappeared in 48 hours and the inflammatory values in the blood decreased significantly. Soon after, the patients were discharged from the hospital fully recovered. One patient had a higher oxygen requirement and was temporarily transferred to the Intensive Care Unit for ventilation, but recovered in the following days and has now left that department.
Dr. Michael Osthoff, from the University Hospital of Basel in Switzerland, discussed an uncontrolled limited treatment that supports Ruconest’s potential effectiveness as an anti-inflammatory.
Following these initial results, an investigator-initiated, randomized, controlled, multinational clinical trial of up to 150 patients with confirmed Covid-19 infections and requiring hospitalization for severe symptoms is planned.
On Monday, Pharming’s stock closed on the Amsterdam stock exchange, just below a higher percentage at 1.0525.
ABM Financial News; [email protected]; Editors: +31 (0) 20 26 28 999.Image: ABM Financial News
